Drug intelligence / Profile preview

Precision NeuroMed infarct penumbra program

Development stage: Preclinical
Lead developer: Precision NeuroMed

Overview

Precision NeuroMed's Infarct Penumbra program is a preclinical-stage neuroprotective initiative aimed at treating acute ischemic stroke. The program focuses on salvaging the "penumbra"—the area of brain tissue surrounding the immediate site of a stroke that is hypoperfused and at risk of dying but remains potentially viable. By targeting the molecular pathways that drive the transition from ischemia to irreversible infarction, the therapy aims to minimize brain damage and improve clinical recovery. The specific molecular target and modality have not been publicly disclosed by the developer, though the company emphasizes a "targeted neuroprotection" approach.

Other names: Infarct Penumbra programPrecision NeuroMed-Infarct Penumbra-Stroke

Beyond the preview

Go deeper on Precision NeuroMed infarct penumbra program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Precision NeuroMed infarct penumbra program.

Explore the full profile